
Biomarkers
AI-native translational medicine
AionWell helps oncology teams weigh early evidence and decide which study to fund next.
Our approach
Follow one early oncology question from the first observation to a funding decision.
Illustrative antibody program
An early antibody program has activity in a selected tumor model. Before the next review, the team can commission a tissue study or a distribution study. Which uncertainty matters more to its choice of indication?
Decision record
Illustrative antibody program
A tissue study can examine variation in target expression. Imaging can examine where a labeled antibody accumulates. Each addresses a different reason the animal finding might fail to translate.
Decision record
Illustrative antibody program
In this example, uncertainty about the population drives the decision. The team prioritizes an independent tissue set and reserves imaging for a later delivery question. The brief records when to revisit that choice.
Decision record
Project inquiries